Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.

@article{Ostenfeld2012HumanME,
  title={Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.},
  author={Thor Ostenfeld and Claire B Beaumont and Jonathan N Bullman and Maria Beaumont and Phillip Jeffrey},
  journal={British journal of clinical pharmacology},
  year={2012},
  volume={74 6},
  pages={
          1033-44
        }
}
AIM The primary objective was to evaluate the pharmacokinetics (PK) of the novel EP(1) antagonist GSK269984A in human volunteers after a single oral and intravenous (i.v.) microdose (100 µg). METHOD GSK269984A was administered to two groups of healthy human volunteers as a single oral (n= 5) or i.v. (n= 5) microdose (100 µg). Blood samples were collected for up to 24 h and the parent drug concentrations were measured in separated plasma using a validated high pressure liquid chromatography… 
Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs.
TLDR
Insight is provided into the usefulness of the preclinical models in enabling pharmacokinetic optimization for acid/zwitterionic drug candidates and an in vitro clearance assay based on human hepatocytes markedly underpredicted human clearance.
Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches.
TLDR
Recently developed approaches to identify and quantification of metabolites in samples from classical human PK studies using technologies suitable for non-radiolabelled drug molecules, namely liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy are described.
The application of human phase 0 microdosing trials: A systematic review and perspectives
TLDR
This review investigates the current application of phase 0 trials in medical research, finding that new ongoing trials are investigating the pharmacodynamics and chemoresistance of marketed drugs, suggesting that the application ofphase 0 trials is still evolving.
Microdosing and drug development: past, present and future
TLDR
Evidence so far suggests that microdosing may be a better predictive tool of human pharmacokinetics than alternative methods and combination with physiologically based modelling may lead to much more reliable predictions in the future.
A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes
TLDR
The method offers an alternative approach to more accurately predict human hepatic clearance when multiple complex mechanisms are involved and is the first time that multiple compounds result in good in vitro–in vivo extrapolation using an entirely “bottom-up” approach without any empirical scaling factor when transporter-mediated clearance is involved.
Phase 0/microdosing approaches: time for mainstream application in drug development?
TLDR
The fundamentals and applications of phase 0 approaches are discussed, the potential advantages of their application in drug development are highlighted and the associated limitations are addressed.
Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans – a practical guide
TLDR
Here a practical guide to the range of methodologies, design options, and conduct strategies that can be used to increase the efficiency of drug development is presented, an improvement over traditional allometric approaches.
Effect of Human Plasma on Hepatic Uptake of Organic Anion–Transporting Polypeptide 1B Substrates: Studies Using Transfected Cells and Primary Human Hepatocytes
TLDR
Insight is offered into the effect of plasma on the uptake clearance and its scope in improving IVIVE, and human plasma facilitates organic anion–transporting polypeptide 1B–mediated as well as passive uptake clearance, particularly for the highly bound compounds.
The Role of PGE2 and its Corresponding Receptors (Ep1-4) in Oesophageal Carcinogenesis: Novel Therapeutics for Chemoprevention and/or Intervention
TLDR
This review will discuss the role of COX-derived PGE2 signalling in OAC development and progression, with specific emphasis on EP receptor expression and function, and compare and contrast the potential of traditional NSAIDs, selectiveCOX-2 inhibitors and EP antagonists as chemopreventive and/or therapeutic agents.
A Review on Microdosing: Reduction in Cost & Time
Now a days as research methods and technology involved in Phase 0 trials become more Sophisticated. Microdosing is an early drug development process where exploratory pharmacokinetic data are
...
1
2
...

References

SHOWING 1-10 OF 45 REFERENCES
A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.
TLDR
Human microdosing provided estimates of clinical PK of four structurally related compounds, which were deemed useful for compound selection.
Microdosing vs. Therapeutic Dosing for Evaluation of Pharmacokinetic Data: A Comparative Study
TLDR
Microdosing PK parameters are comparable to the ones determined by therapeutic dose studies up to a permissible limit, so the idea of phase 0 PK studies supplementing phase 1 PK studies can be furthered.
Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms
TLDR
A retrospective analysis of the data showed that, if the tools had been available at the time, the pharmacokinetics of PF-184298 in human could have been predicted from a population based simulation tool in combination with physicochemical properties and in vitro human intrinsic clearance.
Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma.
TLDR
There is a strong possibility that analysis of metabolites by LC/MS/MS may advance to utilization in microdose clinical trials with non-radioisotope labeled drugs.
Impact of microdosing clinical study -- why necessary and how useful?
TLDR
PET molecular imaging technology further enhances the usability and applicability of the microdose (MD) clinical study by offering the information on efficacy/safety and PBPK model analysis based on the data of both the MD clinical study and in vitro study enables the accurate prediction of PK profiles in humans at the therapeutic dose.
Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.
TLDR
The medicinal chemistry programme to identify a potential back-up compound to the EP(1) receptor antagonist GW848687X resulted in the identification of compound 7i (GSK345931A) which demonstrated good metabolic stability in the rat and lower molecular weight.
Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
  • R. Ings
  • Medicine, Chemistry
    Bioanalysis
  • 2009
TLDR
The rationale and application of the concept of specifically determining the clinical pharmacokinetics of a compound using a very low nonpharmacologically active dose (microdose) with an abridged safety and chemistry, manufacturing and control package is examined.
Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.
TLDR
The quantitative prediction of human hepatic metabolic clearance from in vitro experiments focusing on cytochrome P450 metabolism with eight model compounds is investigated, incorporating additional information from animal studies and providing a more reliable prediction ofhuman hepatic clearance.
Accelerating drug development: methodology to support first‐in‐man pharmacokinetic studies by the use of drug candidate microdosing
TLDR
The results demonstrate the feasibility of applying standard laboratory analytics to support microdosing in humans and raise the possibility of establishing an animal model to screen for compounds having non‐linear pharmacokinetics at low dose levels.
The utility of microdosing over the past 5 years
TLDR
Of the 18 drugs reported, 15 demonstrated linear pharmacokinetics within a factor of 2 between a microdose and a therapeutic dose, suggesting data that support the utility of microdosing are beginning to emerge.
...
1
2
3
4
5
...